MSB 2.10% $1.17 mesoblast limited

MSB to dispute FDA finding in Type A meeting, page-36

  1. 14 Posts.
    lightbulb Created with Sketch. 2
    Thank you @Zenox you have offered a sound and meaningful understanding of the CRL. I did except that it was always going to be a CRL while hoping for straight approval. Never easy. But I do believe that this will tie in nicely with the Covid-19 trail. Perhaps its to have a treatment for both rather then a label extension. Who knows... now that the shock horror is over I still feel confident this will be a success for Mesoblast, patients and us.

    Thanks again always love reading what you have to say
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.